Norges Bank
RXRX icon

Norges Bank’s Recursion Pharmaceuticals RXRX Stock Holding History

Norges Bank’s Portfolio RXRX Stock Details RXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-5,739,064
Closed -$23.5M – 1133
2025
Q4 		$23.5M Buy
+5,739,064
New +$28.4M ﹤0.01% 1207
2025
Q3 		– Sell
-3,169,938
Closed -$16M – 1257
2025
Q2 		$16M Sell
3,169,938
-242,065
-7% -$1.19M ﹤0.01% 1219
2025
Q1 		$18M Sell
3,412,003
-53,872
-2% -$393K ﹤0.01% 1213
2024
Q4 		$23.4M Sell
3,465,875
-106,681
-3% -$717K ﹤0.01% 1207
2024
Q3 		$23.5M Buy
3,572,556
+1,625,261
+83% +$11.7M ﹤0.01% 1194
2024
Q2 		$14.6M Sell
1,947,295
-1,225,247
-39% -$10.7M ﹤0.01% 1293
2024
Q1 		$31.6M Sell
3,172,542
-359,422
-10% -$4M 0.01% 1123
2023
Q4 		$34.8M Buy
3,531,964
+105,708
+3% +$754K 0.01% 1072
2023
Q3 		$26.2M Buy
3,426,256
+559,038
+19% +$5.58M 0.01% 1118
2023
Q2 		$21.4M Sell
2,867,218
-1,358,868
-32% -$9.51M ﹤0.01% 1227
2023
Q1 		$28.2M Sell
4,226,086
-145,227
-3% -$1.15M 0.01% 1107
2022
Q4 		$33.7M Hold
4,371,313
– – 0.01% 1002
2022
Q3 		$46.5M Buy
4,371,313
+116,006
+3% +$1.17M 0.01% 794
2022
Q2 		$34.6M Buy
4,255,307
+2,858,032
+205% +$19.1M 0.01% 960
2022
Q1 		$10M Buy
1,397,275
+1
+0% +$11 ﹤0.01% 1700
2021
Q4 		$23.9M Buy
1,397,274
+897,274
+179% +$16.9M ﹤0.01% 1379
2021
Q3 		$11.5M Hold
500,000
– – ﹤0.01% 1720
2021
Q2 		$18.3M Buy
+500,000
New +$14.8M ﹤0.01% 1581

Other funds holding RXRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
SoftBank Group
SoftBank Group Tokyo, Japan $11.4B AUM 27.91% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
MCMU
MIC Capital Management (UK) London, United Kingdom $352M AUM 0.23% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Norges Bank's RXRX Position: Q1 2026 in Review

Norges Bank sold out of Recursion Pharmaceuticals (RXRX) in Q1 2026, closing a stake of 5,739,064 shares — an estimated $23.5M sold.

Norges Bank first reported a position in RXRX in Q2 2021 and held it in 18 quarters. The position peaked at $46.5M in Q3 2022. 334 funds tracked by Wall St. Rank hold RXRX as of Q1 2026.

  • Norges Bank reported no remaining Recursion Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Norges Bank sold 5,739,064 Recursion Pharmaceuticals shares in Q1 2026, an estimated $23.5M.
  • Norges Bank first reported a position in Recursion Pharmaceuticals in Q2 2021 and held it in 18 quarters.
  • Norges Bank's Recursion Pharmaceuticals position peaked at $46.5M in Q3 2022.
  • 334 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q1 2026.

Based on Norges Bank's 13F filing for Q1 2026.